The European Commission has prepared this paper in order to provide payers, physicians and patients with adequate information on biosimilars. It gives a detailed overview of biologics and biosimilars, regulation and development of biosimilars, potential economic consequences of using biosimilars as well as Q&A sections for each of the key stakeholders.

The introduction of biosimilars has shown that even complex proteins used for chronic disease treatment can be successfully copied. This in turn triggered discussions on aspects such as interchangeability between biosimilars and their reference products as well as immunogenicity profile of biosimilars.

Lorem, ipsum dolor sit amet consectetur adipisicing elit. Ab placeat eveniet aspernatur repudiandae mollitia temporibus doloremque accusantium iusto laudantium earum quia dignissimos distinctio deleniti facilis ullam consequatur, voluptate veritatis perferendis. Aliquid, vel tenetur expedita ullam, inventore odit, magni reprehenderit aperiam reiciendis aspernatur modi perspiciatis eum in animi eaque commodi? Harum, quisquam et. Quod soluta fugit repellendus cum, provident ratione nobis!